GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Net Current Asset Value

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Net Current Asset Value : €4.80 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Laboratorios Farmaceuticos Rovi's net current asset value per share for the quarter that ended in Dec. 2023 was €4.80.

The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Net Current Asset Value or its related term are showing as below:

XMAD:ROVI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.95   Med: 11.5   Max: 17.86
Current: 17.86

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Laboratorios Farmaceuticos Rovi was 17.86. The lowest was 6.95. And the median was 11.50.

XMAD:ROVI's Price-to-Net-Current-Asset-Value is ranked worse than
88.13% of 1036 companies
in the Biotechnology industry
Industry Median: 3.975 vs XMAD:ROVI: 17.86

Laboratorios Farmaceuticos Rovi Net Current Asset Value Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Net Current Asset Value Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.33 2.96 4.46 5.05 4.80

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.99 4.77 5.43 4.80 -

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Net Current Asset Value

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Price-to-Net-Current-Asset-Value falls into.



Laboratorios Farmaceuticos Rovi Net Current Asset Value Calculation

Laboratorios Farmaceuticos Rovi's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(509.331-256.39-4.107-0)/51.8201
=4.80

Laboratorios Farmaceuticos Rovi's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(509.331-256.39-4.107-0)/51.8201
=4.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Laboratorios Farmaceuticos Rovi Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Headlines

From GuruFocus

Rovi Corp. (ROVI) EVP & CFO James Budge sells 10,833 Shares

By GuruFocus Research GuruFocus Editor 02-03-2011

Rovi Corp. (ROVI) EVP & CFO James Budge sells 44,145 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 33,957 Shares

By GuruFocus Research GuruFocus Editor 02-03-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 200,000 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011

Rovi Corp: Profitability in Times of Change

By Damian Illia Damian Illia 02-19-2014

George Soros Buys Rovi Corp

By Kyle Ferguson Kyle Ferguson 09-08-2016

TiVo Corporation to Announce First Quarter 2020 Results

By Business Wire Business Wire 04-23-2020

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 33,957 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011